KR20120105429A - 염증 치료 방법 - Google Patents

염증 치료 방법 Download PDF

Info

Publication number
KR20120105429A
KR20120105429A KR1020127010455A KR20127010455A KR20120105429A KR 20120105429 A KR20120105429 A KR 20120105429A KR 1020127010455 A KR1020127010455 A KR 1020127010455A KR 20127010455 A KR20127010455 A KR 20127010455A KR 20120105429 A KR20120105429 A KR 20120105429A
Authority
KR
South Korea
Prior art keywords
mif
peptide
disease
seq
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127010455A
Other languages
English (en)
Korean (ko)
Inventor
위르겐 베른하겐
크리스티안 베버
베네딕트 폴라트
코트 터너
조슈야 로버트 슐츠
알마 체르네케
세르히오 듀론
Original Assignee
카롤러스 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카롤러스 테라퓨틱스, 인코포레이티드 filed Critical 카롤러스 테라퓨틱스, 인코포레이티드
Publication of KR20120105429A publication Critical patent/KR20120105429A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020127010455A 2009-09-23 2010-09-23 염증 치료 방법 Withdrawn KR20120105429A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US61/245,214 2009-09-23
US31903910P 2010-03-30 2010-03-30
US61/319,039 2010-03-30

Publications (1)

Publication Number Publication Date
KR20120105429A true KR20120105429A (ko) 2012-09-25

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127010455A Withdrawn KR20120105429A (ko) 2009-09-23 2010-09-23 염증 치료 방법

Country Status (9)

Country Link
EP (1) EP2480579A4 (OSRAM)
KR (1) KR20120105429A (OSRAM)
CN (1) CN102725311A (OSRAM)
AU (1) AU2010298249A1 (OSRAM)
BR (1) BR112012006468A2 (OSRAM)
CA (1) CA2773978A1 (OSRAM)
IN (1) IN2012DN02423A (OSRAM)
MX (1) MX2012003514A (OSRAM)
WO (1) WO2011038149A2 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
TW201605886A (zh) * 2013-11-14 2016-02-16 巴克斯特保健公司 作爲治療標靶的ｍｉｆ
CN113893252A (zh) 2016-03-11 2022-01-07 阿迪亚生命科学公司 用于治疗结晶性关节病症的cxcr-2抑制剂
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
AU2019417313B2 (en) * 2018-12-26 2023-01-19 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
KR20220166809A (ko) * 2020-03-11 2022-12-19 바이오라인알엑스 리미티드 급성 호흡곤란 증후군 및 바이러스 감염 치료를 위한 cxcr4 억제제
US20210338626A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (zh) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 多肽at03在治疗原发性胆汁性胆管炎药物中的应用
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides
CN119318647A (zh) * 2024-08-14 2025-01-17 南方医科大学 Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
WO2003072753A2 (en) * 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
EP1483294B2 (en) * 2002-03-01 2019-10-30 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
WO2010056910A2 (en) * 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Also Published As

Publication number Publication date
MX2012003514A (es) 2012-04-19
CA2773978A1 (en) 2011-03-31
CN102725311A (zh) 2012-10-10
BR112012006468A2 (pt) 2016-08-09
WO2011038149A3 (en) 2011-10-27
AU2010298249A1 (en) 2012-04-19
EP2480579A2 (en) 2012-08-01
EP2480579A4 (en) 2013-07-31
WO2011038149A2 (en) 2011-03-31
IN2012DN02423A (OSRAM) 2015-08-21

Similar Documents

Publication Publication Date Title
US20110262386A1 (en) Methods of treating inflammation
KR20120105429A (ko) 염증 치료 방법
US20100093636A1 (en) Methods of treating inflammation
US20110256130A1 (en) Methods of treating inflammatory disorders
CN103459595B (zh) 针对人前列腺素e2受体ep4的抗体
TW201829461A (zh) 中和抗tl1a之單株抗體
AU2017347822B2 (en) Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody
BR112020020118A2 (pt) composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1.
KR20250067121A (ko) Cnx 항원-결합 분자
WO2011116245A2 (en) Methods of treating inflammation
US20240294633A1 (en) Antibody specific for anti-bcl-6 antibody and methods of use
JP7458049B2 (ja) 自己免疫疾患治療剤
WO2024005204A1 (ja) 融合タンパク質

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid